Spyre Therapeutics (SYRE) Competitors $14.78 -0.62 (-4.03%) Closing price 04:00 PM EasternExtended Trading$14.78 0.00 (-0.03%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYRE vs. SRPT, RNA, SWTX, RARE, AKRO, ACLX, ZLAB, VKTX, CRNX, and ALVOShould you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include Sarepta Therapeutics (SRPT), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), Arcellx (ACLX), Zai Lab (ZLAB), Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry. Spyre Therapeutics vs. Sarepta Therapeutics Avidity Biosciences SpringWorks Therapeutics Ultragenyx Pharmaceutical Akero Therapeutics Arcellx Zai Lab Viking Therapeutics Crinetics Pharmaceuticals Alvotech Sarepta Therapeutics (NASDAQ:SRPT) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Which has more volatility and risk, SRPT or SYRE? Sarepta Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.78, meaning that its stock price is 178% more volatile than the S&P 500. Does the media favor SRPT or SYRE? In the previous week, Sarepta Therapeutics had 10 more articles in the media than Spyre Therapeutics. MarketBeat recorded 16 mentions for Sarepta Therapeutics and 6 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 1.64 beat Sarepta Therapeutics' score of 1.04 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 10 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is SRPT or SYRE more profitable? Sarepta Therapeutics has a net margin of 7.43% compared to Spyre Therapeutics' net margin of 0.00%. Sarepta Therapeutics' return on equity of 11.00% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sarepta Therapeutics7.43% 11.00% 3.35% Spyre Therapeutics N/A -210.01%-44.40% Does the MarketBeat Community believe in SRPT or SYRE? Sarepta Therapeutics received 1460 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 75.04% of users gave Sarepta Therapeutics an outperform vote. CompanyUnderperformOutperformSarepta TherapeuticsOutperform Votes148275.04% Underperform Votes49324.96% Spyre TherapeuticsOutperform Votes22100.00% Underperform VotesNo Votes Do institutionals and insiders hold more shares of SRPT or SYRE? 86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 7.7% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 15.4% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better earnings and valuation, SRPT or SYRE? Spyre Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSarepta Therapeutics$2.23B1.76-$535.98M-$2.69-14.89Spyre Therapeutics$890K1,000.99-$338.79M-$3.77-3.92 Do analysts prefer SRPT or SYRE? Sarepta Therapeutics presently has a consensus price target of $122.61, indicating a potential upside of 206.14%. Spyre Therapeutics has a consensus price target of $53.40, indicating a potential upside of 261.30%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spyre Therapeutics is more favorable than Sarepta Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 0 Sell rating(s) 5 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.83Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 SummarySarepta Therapeutics beats Spyre Therapeutics on 10 of the 19 factors compared between the two stocks. Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRE vs. The Competition Export to ExcelMetricSpyre TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$890.88M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-1.988.9226.8419.71Price / Sales1,000.99253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book-67.186.466.794.50Net Income-$338.79M$143.98M$3.23B$248.18M7 Day Performance-0.14%3.04%4.07%1.14%1 Month Performance8.92%7.44%12.52%15.20%1 Year Performance-59.05%-2.46%16.83%6.56% Spyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRESpyre Therapeutics2.3323 of 5 stars$14.78-4.0%$53.40+261.3%-58.2%$890.88M$890,000.00-1.98100Positive NewsGap DownSRPTSarepta Therapeutics4.8302 of 5 stars$36.37+0.3%$131.22+260.8%-69.4%$3.57B$2.23B29.10840Positive NewsAnalyst ForecastGap UpHigh Trading VolumeRNAAvidity Biosciences1.905 of 5 stars$29.33+5.2%$66.38+126.3%+8.2%$3.53B$10.90M-10.18190Options VolumeGap UpSWTXSpringWorks Therapeutics2.3618 of 5 stars$46.12-0.3%$52.57+14.0%+9.1%$3.46B$191.59M-13.25230Positive NewsHigh Trading VolumeRAREUltragenyx Pharmaceutical3.9527 of 5 stars$36.09+2.8%$90.93+152.0%-10.1%$3.32B$590.69M-5.691,310Positive NewsAKROAkero Therapeutics3.8261 of 5 stars$41.53+4.2%$76.29+83.7%+136.2%$3.31BN/A-11.0730Insider TradeHigh Trading VolumeACLXArcellx1.7682 of 5 stars$59.50+3.4%$109.31+83.7%+11.4%$3.28B$76.81M-83.8080News CoverageZLABZai Lab2.6288 of 5 stars$29.40+0.5%$47.37+61.1%+56.6%$3.24B$418.33M-10.611,950VKTXViking Therapeutics4.4168 of 5 stars$28.30+2.7%$87.15+208.0%-57.5%$3.18BN/A-28.3020Positive NewsCRNXCrinetics Pharmaceuticals3.6589 of 5 stars$33.32+8.6%$73.00+119.1%-38.0%$3.12B$1.04M-8.93210ALVOAlvotech1.752 of 5 stars$10.25+5.9%$18.00+75.6%-27.6%$3.09B$489.68M-5.544High Trading Volume Related Companies and Tools Related Companies SRPT Competitors RNA Competitors SWTX Competitors RARE Competitors AKRO Competitors ACLX Competitors ZLAB Competitors VKTX Competitors CRNX Competitors ALVO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYRE) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SYRE Stock Free SYRE Stock Alerts